Avadel Pharmaceuticals (AVDL)
(Real Time Quote from BATS)
$13.55 USD
-0.05 (-0.37%)
Updated Sep 20, 2024 03:00 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Avadel Pharmaceuticals PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -160.28 | -137.46 | -77.33 | 7.03 | -33.23 |
Depreciation/Amortization & Depletion | 1.77 | 1.49 | 0.82 | 1.69 | 2.53 |
Net Change from Assets/Liabilities | -3.00 | 24.54 | 3.70 | -14.32 | -10.48 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 33.00 | 41.13 | -4.49 | -43.13 | 2.86 |
Net Cash From Operating Activities | -128.51 | -70.30 | -77.31 | -48.73 | -38.33 |
Property & Equipment | 0.00 | -0.72 | -0.03 | -0.10 | 0.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 16.50 | 25.50 | 0.00 |
Investments | -50.09 | 80.41 | 40.46 | -95.12 | 38.60 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -50.09 | 79.70 | 56.93 | -69.72 | 38.72 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 148.36 | 28.00 | 0.26 | 179.68 | 0.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | -8.65 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -13.02 | -4.80 | 0.00 | 0.00 | -0.15 |
Net Cash from Financing Activities | 135.34 | 14.54 | 0.26 | 179.68 | -0.03 |
Effect of Exchange Rate Changes | 0.46 | -0.66 | -0.90 | 0.72 | 0.08 |
Net Change In Cash & Equivalents | -42.81 | 23.27 | -21.01 | 61.95 | 0.45 |
Cash at Beginning of Period | 73.98 | 50.71 | 71.72 | 9.77 | 9.33 |
Cash at End of Period | 31.17 | 73.98 | 50.71 | 71.72 | 9.77 |
Diluted Net EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 |
Fiscal Year End for Avadel Pharmaceuticals PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -41.16 | -27.34 | -160.28 | -131.49 | -95.22 |
Depreciation/Amortization & Depletion | 0.98 | 0.54 | 1.77 | 1.78 | 1.19 |
Net Change from Assets/Liabilities | -17.35 | -7.57 | -3.00 | 1.36 | 6.97 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.64 | 4.67 | 33.00 | 27.87 | 24.80 |
Net Cash From Operating Activities | -47.89 | -29.70 | -128.51 | -100.48 | -62.26 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 31.94 | 21.39 | -50.09 | -78.02 | -87.84 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 31.94 | 21.39 | -50.09 | -78.02 | -87.84 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 13.91 | 13.19 | 148.36 | 148.30 | 147.84 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -17.50 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -13.02 | 8.14 | -4.36 |
Net Cash from Financing Activities | 13.91 | 13.19 | 135.34 | 156.45 | 125.99 |
Effect of Exchange Rate Changes | -0.28 | -0.25 | 0.46 | -0.11 | 0.12 |
Net Change In Cash & Equivalents | -2.32 | 4.63 | -42.81 | -22.17 | -24.00 |
Cash at Beginning of Period | 31.17 | 31.17 | 73.98 | 73.98 | 73.98 |
Cash at End of Period | 28.85 | 35.79 | 31.17 | 51.81 | 49.99 |
Diluted Net EPS | -0.14 | -0.30 | -0.28 | -0.41 | -0.83 |